Angiotensin II Type 1 Receptor Blockade Inhibits Gastric Cancer Metastasis Through Tight Junction Restoration
Sooraj Kakkat, Prabhat Suman, Sandeep GoswamiiD, Brusi Kola, Kira Bruno, Wendy L. FrankeliD, Sujit BasuiD, Elba A. Turbat‐Herrera, Verónica Ramírez‐AlcántaraiD, Martin J. HesliniD, Joel AndrewsiD, Paramahansa PramanikiD, Chandrani SarkariD, Debanjan ChakrobortyiD
Abstract
Cell-Cell adhesion maintained by tight junctions (TJs) is essential for epithelial integrity; loss of TJs correlates with poor prognosis, metastasis, and adverse clinical outcome in gastric cancer (GC). Restoring TJ integrity is therefore considered a promising therapeutic strategy in GC. The study identifies the stomach renin angiotensin system (stRAS) as a crucial regulator of TJ function in GC. Using integrative analysis of GC patient tissues, human GC cell lines, and orthotopic GC xenograft models, here we show that angiotensin II (ATII), the principal effector peptide of stRAS, drives TJ disassembly through an autocrine loop involving angiotensin receptor type 1 (AT1R) expressed on GC cells. Both ATII and AT1R are overexpressed in GC, where they suppress the expression of key TJ proteins. By analyzing global RNA-sequencing (RNA-seq) data and performing CRISPR/Cas9 gene deletion, chromatin immunoprecipitation, and functional assays, we mechanistically reveal that ATII, which is predominantly produced by cancer cells within the tumor microenvironment (TME), inhibits the expression of kruppel-like factor 4 (KLF4), a transcription factor crucial for the transcription of key TJ genes (CLDN1, 3, 4, and TJP1), leading to reduced synthesis of TJ proteins via AT1R expressed on cancer cells. Notably, the study demonstrates the effectiveness of pharmacological inhibition of AT1R with clinically established AT1R antagonists in preventing GC growth and metastasis by restoring TJ stability in vivo. These findings delineate a previously unrecognized role for ATII in governing TJ disassembly in GC and highlight the ATII/AT1R axis as a promising therapeutic target. GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=149 SRC="FIGDIR/small/698396v3_ufig1.gif" ALT="Figure 1000"> View larger version (33K): org.highwire.dtl.DTLVardef@a1b9adorg.highwire.dtl.DTLVardef@1a53c5dorg.highwire.dtl.DTLVardef@11e3e1corg.highwire.dtl.DTLVardef@7fd735_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- FWCI
- 0.00
- Field percentile
- 32th percentile
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Inhibition of the tuft cell/ILC2 axis reduces gastric tumor development in mice
R. N. O'Keefe, A. Carli, … M. Buchert·bioRxiv·Feb 16, 2022
- Mechanism of N-Myc Downstream Regulated Gene-1 regulating Integrin expression to inhibit gastric cancer metastasis
Tengkai Wang, Wenlong Ma, … Jiaoyang Lu·bioRxiv·Oct 23, 2024
- Von Willebrand Factor Synergizes with Tumor-Derived Extracellular Vesicles to Promote Gastric Cancer Metastasis
- Migration of gastric cancer is suppressed by rabies virus glycoprotein via regulating α7-nicotinic acetylcholine receptors/ERK-EMT
X. Bu, A. Zhang, … Y. Yan·BMC CancerPeer-reviewed·Oct 22, 2019
- VPAC1 couples with TRPV4 channel to promote calcium-dependent gastric cancer progression
- Tegaserod maleate suppresses the growth of gastric cancer in vivo and in vitro by targeting MEK1/2
K. Liu, y. jiang, … y. chen·CancersPeer-reviewed·Jul 23, 2022